Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of shareholders of Vital Therapies, Inc. (“Vital Therapies”) (NASDAQ:VTL) who purchased their shares between April 17, 2014 and August 21, 2015.
The complaint alleges that throughout the class period, defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (a) the studies’ independent significance; (b) the degree to which the studies were interrelated; and (c) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
On August 21, 2015, after the market closed, Vital Therapies announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days…” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, Vital Therapies shares plunged 73.4% to close at just $3.65 per share the next trading day.
If you suffered a loss in Vital Therapies you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vital-therapies.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
